Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
April 28, 2026Pamplona/MadridIn recruitment
-
April 22, 2026PamplonaIn recruitment
IVY-P3-24-021 A Phase III, open-label, randomized, two-arm clinical trial to compare the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly diagnosed MGMT-unmethylated glioblastoma
This is a Phase III trial. This trial consists of: Phase 1, during which participants will receive either the study drug or the comparator drug, and all participants will also receive radiation therapy; and Phase 2, during which participants will continue to receive the same drug they received in Phase 1, without radiation therapy. -
April 22, 2026MadridIn recruitmentEarly phase
PHN-012-001 Clinical trial of PHN-012 in patients with advanced solid tumors.
The primary objective is to determine the MTD or MAD for intravenous PHN-012 monotherapy and to evaluate its safety and tolerability. -
April 21, 2026Pamplona/MadridIn recruitment
M25-586 A clinical trial to evaluate the efficacy and safety of etentamig and daratumumab (etentamig) compared with daratumumab, lenalidomide, and dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are not eligible for transplantation.
The objective of this study is to determine whether etentamig is safe and to identify the optimal dose of etentamig when combined with daratumumab in participants with newly diagnosed multiple myeloma (NDMM) who are not eligible for transplantation. -
April 20, 2026PamplonaIn recruitment
IDE196-010 A randomized, open-label Phase 3 clinical trial to evaluate darovasertib as a neoadjuvant treatment in patients with non-metastatic primary uveal melanoma (OptimUM-10)
The aim of the study is to determine whether the experimental drug called darovasertib (also known as IDE196) is safe and effective in people with a specific type of eye cancer called uveal melanoma (UM). -
April 15, 2026Pamplona/MadridIn recruitmentEarly phase
EXS73565-001 A Phase I, open-label, multicenter, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of EXS73565 in participants with lymphocytic malignancies.
The purpose of this clinical trial is to investigate the drug’s safety, how well you tolerate the drug, and its antitumor activity, and to determine the optimal dose when administered daily as an oral tablet. -
April 14, 2026Pamplona/MadridIn recruitment
RPTR-1-201-101 Phase I/II clinical trial of RPTR-1-201, a bispecific T-cell receptor therapy, in patients with advanced solid tumors.
The main goal of this clinical research trial is to determine whether the investigational drug, RPTR-1-201, is safe and what side effects it may cause. In some parts of the trial, RPTR-1-201 will be given alone, and in other parts, it will be given together with another cancer drug called pembrolizumab. The goal is to assess the safety of RPTR-1-201 when used alone and when used together with pembrolizumab. -
April 14, 2026Pamplona/MadridIn recruitment
BNT327-05 A Phase III, multicenter, randomized, double-blind clinical trial of BNT327 in combination with chemotherapy versus placebo plus chemotherapy in patients with triple-negative breast cancer (TNBC).
The aim of this study is to compare the effects of the study drug, pumitamig (also known as BNT327 or PM8002), with those of a placebo, when both are administered in combination with chemotherapy. -
April 7, 2026Pamplona/MadridIn recruitment
DS6000-109 Clinical trial to evaluate raludotatug deruxtecan (R-DXd) in participants with rapidly progressing ovarian cancer, primary peritoneal cancer, or platinum-resistant fallopian tube cancer.
The primary objective is to evaluate raludotatug deruxtecan, also known as R-DXd, at each dose level. -
April 6, 2026Pamplona/MadridIn recruitmentEarly phase
GEM-CAR-HIRISMM A Phase II, open-label, single-arm, multicenter study of Ciltacabtagene Autoleucel in high-risk quiescent multiple myeloma
The aim of this study is to investigate the safety and efficacy of the Dara-VRD regimen followed by Ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy, in patients diagnosed with high-risk MMq.